David Thompson - EXACT Sciences Lead Independent Director
| EXAS Stock | USD 60.22 0.21 0.35% |
Director
Mr. David A. Thompson is Lead Independent Director of the Company. He has served as a director since July 2010 and as lead independent director since March 2014. He was the chairman and lead independent director of Third Wave Technologies, Inc., a molecular diagnostics company, from 2005 until its acquisition by Hologic, Inc. in July 2008. Prior to that, he retired in 1995 from Abbott Laboratories, a diversified healthcare company, where he worked for more than 30 years. He held several corporate officer positions within Abbott, including senior vice president and president diagnostic division, vice president human resources, vice president corporate materials management and vice president operations. Mr. Thompson previously served as the lead director of St. Jude Medical, Inc., a medical technology and services company, and as a director of each of Hycor Biomedical, Inc., a medical diagnostic products company, LifeCell Corporationrationration, a biological products company, NABI, a biopharmaceutical company, and TriPath Imaging, Inc., an automated imaging company since 2014.
| Age | 76 |
| Tenure | 10 years |
| Address | 5505 Endeavor Lane, Madison, WI, United States, 53719 |
| Phone | 608 284 5700 |
| Web | https://www.exactsciences.com |
David Thompson Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Thompson against EXACT Sciences stock is an integral part of due diligence when investing in EXACT Sciences. David Thompson insider activity provides valuable insight into whether EXACT Sciences is net buyers or sellers over its current business cycle. Note, EXACT Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell EXACT Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Thompson over two months ago Bona fide gift to David Thompson of 100000 shares of American Financial subject to Section 16 |
EXACT Sciences Management Efficiency
The company has return on total asset (ROA) of (0.0304) % which means that it has lost $0.0304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, EXACT Sciences' Debt To Assets are comparatively stable compared to the past year. Asset Turnover is likely to gain to 0.41 in 2024, whereas Return On Tangible Assets are likely to drop (0.1) in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gary Guthart | Illumina | 52 | |
| John Steuart | Natera Inc | 55 | |
| Louise Phanstiel | Myriad Genetics | 59 | |
| Mai Xiaoying | Twist Bioscience Corp | 30 | |
| Aaref Hilaly | Guardant Health | 46 | |
| George Bickerstaff | Caredx Inc | 62 | |
| James Mullen | Thermo Fisher Scientific | 62 | |
| Stanley Meresman | Guardant Health | 71 | |
| Alan Spoon | Danaher | 69 | |
| Nelson Chai | Thermo Fisher Scientific | 55 | |
| Lars Sorensen | Thermo Fisher Scientific | 67 | |
| Dipchand Nishar | Guardant Health | N/A | |
| William Parrett | Thermo Fisher Scientific | 71 | |
| Heiner Dreismann | Myriad Genetics | 64 | |
| Susan Siegel | Illumina | 57 | |
| Jonathan Sheena | Natera Inc | 45 | |
| Jan Johannessen | Twist Bioscience Corp | 62 | |
| Robert Hugin | Danaher | 61 | |
| Roy Baynes | Natera Inc | 63 | |
| Robert Ragusa | Twist Bioscience Corp | 58 | |
| Linda Filler | Danaher | 61 | |
Management Performance
| Return On Equity | -0.066 | ||||
| Return On Asset | -0.0304 |
EXACT Sciences Leadership Team
Elected by the shareholders, the EXACT Sciences' board of directors comprises two types of representatives: EXACT Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EXACT. The board's role is to monitor EXACT Sciences' management team and ensure that shareholders' interests are well served. EXACT Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EXACT Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Katherine Napier, Independent Director | ||
| Sally Crawford, Independent Director | ||
| Jeffrey Elliott, CFO | ||
| Kevin Conroy, Chairman of The Board, CEO and Pres | ||
| James Doyle, Independent Director | ||
| Ana Hooker, Senior Vice President Operations | ||
| Thomas Carey, Independent Director | ||
| John Fallon, Director | ||
| Scott Johnson, Senior Vice President Research & Development | ||
| Daniel Levangie, Independent Director | ||
| Vic Parker, Head Sales | ||
| John Bakewell, CFO | ||
| Sri Kalluri, Chief Officer | ||
| Nassar Nizami, Chief Officer | ||
| William Megan, Principal Financial Officer and Sr. VP of Fin. | ||
| Scott Coward, Sr. VP and General Counsel | ||
| Pierre Jacquet, Director | ||
| Graham Lidgard, Chief Science Officer and Sr. VP | ||
| Jorge Garces, Chief Officer | ||
| Jeffrey CFA, Chief Officer | ||
| David Thompson, Lead Independent Director | ||
| Michael Wyzga, Director | ||
| Lionel Sterling, Independent Director | ||
| James Herriott, General VP | ||
| Andrew Slavitt, Director | ||
| Sarah Condella, Executive Resources | ||
| Mark Stenhouse, President Cologuard | ||
| Tim Caprez, Chief VP | ||
| Kathleen Sebelius, Director | ||
| Everett Cunningham, Chief Officer | ||
| Maneesh Arora, COO, Sr. VP and Director | ||
| Katherine Zanotti, Independent Director | ||
| Eli Casdin, Independent Director | ||
| Megan Jones, Associate Relations |
EXACT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EXACT Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.066 | ||||
| Return On Asset | -0.0304 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 12.68 B | ||||
| Shares Outstanding | 183.85 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 90.60 % | ||||
| Number Of Shares Shorted | 9.89 M | ||||
| Price To Earning | (38.17) X |
Pair Trading with EXACT Sciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EXACT Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EXACT Sciences will appreciate offsetting losses from the drop in the long position's value.Moving together with EXACT Stock
| 0.72 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
Moving against EXACT Stock
| 0.63 | LFCR | Lifecore Biomedical Financial Report 6th of June 2024 | PairCorr |
| 0.58 | HOWL | Werewolf Therapeutics Earnings Call This Week | PairCorr |
| 0.56 | MBRX | Moleculin Biotech Financial Report 9th of May 2024 | PairCorr |
| 0.41 | IKNA | Ikena Oncology Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to EXACT Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EXACT Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EXACT Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EXACT Sciences to buy it.
The correlation of EXACT Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EXACT Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EXACT Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EXACT Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy EXACT Stock please use our How to Invest in EXACT Sciences guide.Note that the EXACT Sciences information on this page should be used as a complementary analysis to other EXACT Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for EXACT Stock analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is EXACT Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EXACT Sciences. If investors know EXACT will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EXACT Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.13) | Revenue Per Share 13.876 | Quarterly Revenue Growth 0.17 | Return On Assets (0.03) | Return On Equity (0.07) |
The market value of EXACT Sciences is measured differently than its book value, which is the value of EXACT that is recorded on the company's balance sheet. Investors also form their own opinion of EXACT Sciences' value that differs from its market value or its book value, called intrinsic value, which is EXACT Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EXACT Sciences' market value can be influenced by many factors that don't directly affect EXACT Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between EXACT Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if EXACT Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EXACT Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.